Dofetilide

454 interactions 653 cited references

Also sold as: Tikosyn Tikosyn®

About Dofetilide

Dofetilide is an antiarrhythmic medication used to treat irregular heartbeats like atrial fibrillation or atrial flutter. Read the full Dofetilide drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Sulfamethoxazole Cisapride Bictegravir Cimetidine Sparfloxacin Saquinavir

33 Contraindicated 288 Major 131 Moderate 2 Minor

All (454) Contraindicated (33) Major (288) Moderate (131) Minor (2)

Major

Dofetilide Isradipine DynaCirc® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Ivabradine Corlanor Increased risk of QT prolongation Details Dofetilide Ivacaftor Kalydeco Increased CYP3A substrate exposure Details Dofetilide Ivosidenib Tibsovo An increased risk of QT interval prolongation Details Dofetilide Lacosamide Motpoly An increased risk of AV block, bradycardia, and ventricular tachyarrhythmia Details Dofetilide Lamotrigine Lamictal Increased dofetilide exposure Details Dofetilide Lanreotide Altered exposure to CYP3A4 substrate Details Dofetilide Lapatinib Tykerb Increased dofetilide plasma concentrations and an increased risk of QT interval prolongation Details Dofetilide Lazertinib Lazcluze Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Dofetilide Lefamulin Xenleta Increased dofetilide exposure and an increased risk of QT interval prolongation Details Dofetilide Lenvatinib Lenvima Increased risk of QT-interval prolongation Details Dofetilide Letermovir Prevymis Increased CYP3A substrate exposure Details Dofetilide Leuprolide Eligard Increased risk of QT interval prolongation Details Dofetilide Levofloxacin Levaquin An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Lidoflazine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Lofexidine Increased risk of QT interval prolongation Details Dofetilide Lonafarnib Zokinvy Increased CYP3A substrate with NTI exposure, an increased risk of CYP3A substrate with NTI-related serious or life-threatening tox... Details Dofetilide Loperamide Diamode An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Dofetilide Lopinavir An increased risk of QT interval prolongation Details Dofetilide Lorcainide An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Lorlatinib Lorbrena Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Dofetilide Lumefantrine An increased risk of QT interval prolongation Details Dofetilide Macimorelin Increased risk of QT interval prolongation Details Dofetilide Mavorixafor Xolremdi Increased CYP3A4 substrate with NTI exposure, increased risk of CYP3A4 with NTI-related adverse events and an increased risk of QT... Details Dofetilide Mefloquine Lariam® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Metformin Fortamet® Increased dofetilide exposure and an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Methadone Diskets An increased risk of QT interval prolongation Details Dofetilide Methotrimeprazine An increased risk of QT interval prolongation Details Dofetilide Metronidazole Flagyl An increased risk of QT interval prolongation Details Dofetilide Milsaperidone An increased risk of QT interval prolongation Details Dofetilide Mirtazapine Mirataz Increased risk of QT interval prolongation and torsades de pointes Details Dofetilide Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Dofetilide Mitotane Lysodren Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI exposure Details Dofetilide Mizolastine An increased risk of QT interval prolongation Details Dofetilide Mobocertinib Exkivity Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure; QT interval prolongation Details Dofetilide Moricizine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Moxifloxacin Avelox Increased risk of QT interval prolongation Details Dofetilide Nelfinavir Viracept Increased risk of QT interval prolongation Details Dofetilide Netupitant Increased exposure of CYP3A4 substrate Details Dofetilide Nilotinib Increased dofetilide exposure and an increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.